China Biologic Products
Beijing, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Major Chinese plasma fractionator producing essential biologics like albumin and immunoglobulins.
HematologyBiologics
Technology Platform
Large-scale plasma fractionation and purification platform for manufacturing a portfolio of plasma-derived therapeutic proteins.
Opportunities
Continued growth from China's structural supply-demand gap for plasma products and potential expansion into higher-margin specialty immunoglobulins.
Risk Factors
Heavily reliant on the costly and logistically complex collection of plasma, and vulnerable to changes in government procurement and pricing regulations.
Competitive Landscape
Competes in an oligopolistic market with a few dominant domestic fractionators and faces ongoing pricing pressure from national volume-based procurement policies.